Response to therapy was not predicted by the initial, preexposure, or anti-pFVIII titer. This was observed for several parameters reflecting treatment response, including first-dose recovery FVIII activity after dosing (A), total rpFVIII dose required in the first 24 hours for hemostasis (B), and cumulative rpFVIII dose required for bleed episode (C). There does seem to be a trend up in cumulative rpFVIII dose and the peak anti-pFVIII antibody titer. Note: Three patients did not have a preexposure pBIA and are not included in this figure (Table 1). Patients 7 and 9 received different initial doses than outlined in our algorithm and are likewise not included in these figures. low indicates ≤5 BU; high, >5 BU. (A) First-dose recovery vs preexposure pBIA. (B) rpFVIII dose in first 24 hours vs preexposure pBIA. (C) Cumulative rpFVIII dose for bleed vs preexposure pBIA.